2009
DOI: 10.1111/j.1533-2500.2008.00245.x
|View full text |Cite
|
Sign up to set email alerts
|

The Danish version of the Medication Adherence Report Scale: Preliminary Validation in Cancer Pain Patients

Abstract: The DMARS-4 seems to be a valid and reliable measure of self-reported adherence to analgesic regimen in the context of cancer pain.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
9
0
5

Year Published

2010
2010
2020
2020

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 17 publications
(16 citation statements)
references
References 44 publications
2
9
0
5
Order By: Relevance
“…The MARS has been used as a self-reported measure of adherence in a number of chronic diseases, including chronic obstructive pulmonary disease,38 asthma,39 chronic pain management in cancer,40 bipolar disorder,17 and inflammatory bowel disease 41,42. The MARS includes a preamble encouraging honest responses.…”
Section: Methodsmentioning
confidence: 99%
“…The MARS has been used as a self-reported measure of adherence in a number of chronic diseases, including chronic obstructive pulmonary disease,38 asthma,39 chronic pain management in cancer,40 bipolar disorder,17 and inflammatory bowel disease 41,42. The MARS includes a preamble encouraging honest responses.…”
Section: Methodsmentioning
confidence: 99%
“…Medication adherence will be evaluated by use of a Danish version of The Medication Adherence Report Scale (DMARS-4). This is a generic scale as yet solely validated to cancer patients in relation to their analgesic treatment [40]. In addition the two group’s primary medication adherence at follow up will be evaluated by gathering of register data from the Danish Medicines Agency [12].…”
Section: Methodsmentioning
confidence: 99%
“…The generic scale covers whether respondents avoid, forget, alter or discontinue the prescribed medication. Measurement of the four items is on a five-point Likert scale (26).…”
Section: Demographics Susceptibility and Dermatological Treatmentmentioning
confidence: 99%